Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants

A Phase 1, Open-label Study to Evaluate the Effect of Rifampin on the Single Dose Pharmacokinetics, Safety, and Tolerability of BMS-986235 in Healthy Participants

The purpose of this study is to examine the effect of rifampin on the drug levels in blood and safety of BMS-986235, when taken by healthy participants.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy participants, as determined by no clinically significant deviation from normal in physical examination, ECGs, and clinical laboratory determinations; no significant findings in medical history.
• Body mass index of 18.0 kg/m2 to 30.0 kg/m2, inclusive, at screening
• Males must agree to follow specific methods of contraception, if applicable

Exclusion Criteria:

• Women of childbearing potential (WOCBP)
• Known previous exposure to BMS-986235
• History of any significant drug allergy

Other protocol-defined inclusion/exclusion criteria apply